The authors of a recent study report that the addition of a disease-modifying anti-rheumatic drug (DMARD) or a switch to ustekinumab showed greater efficacy than changing anti–tumor necrosis factor (anti-TNF) treatments in patients with inflammatory bowel disease (IBD) who develop paradoxical arthritis.
Patients who receive treatment with anti—tumor necrosis factor (anti-TNF) drugs for inflammatory bowel disease (IBD) may develop arthritis, despite the fact that anti-TNFs can be used successfully to treat conditions such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Currently, there are no predictors of paradoxical arthritis, and optimal clinical management is debated.
A recent study sought to evaluate the histological features of paired synovial tissue and colonic mucosa tissue in patients who have IBD and develop paradoxical arthritis while undergoing treatment.
Patients with Crohn disease (CD) or ulcerative colitis (UC) who were in stable clinical or endoscopic remission, and who had no history of joint involvement but developed paradoxical arthritis during maintenance therapy with anti-TNFs, were enrolled in a prospective study from January 2015 to April 2017. In total, 10 patients with IBD (6 with CD and 4 with UC) were enrolled.
The patients underwent rheumatological evaluation and immunological parameters were recorded, and they also underwent ultrasound assessment. A multidisciplinary team recommended 1 of 3 treatment modifications for these patients: the addition of a disease-modifying anti-rheumatic drug (DMARD), either methotrexate or sulphasalazine; a switch to a different anti-TNF agent; or a switch to ustekinumab. Patients were followed every 2 months for at least 6 months.
Ultrasound assessment showed that there were no significant differences between patients with IBD who developed arthritis while taking anti-TNFs than in patients with PsA or RA, but the patients showed greater similarity, in terms of tender joint count and swollen joint count, to PsA than to RA. They also showed similar histological findings in terms of synovial-resident CD68+, CD21+, CD20+, CD3+, and CD117+ cells versus comparator patients who had PsA or RA.
Additionally, the colonic mucosa (CM) of patients with IBD showed signs of histologically proven subclinical inflammation, even in the case of clinical and endoscopic remission or mild disease activity. All of the patients with IBD had CD68+ cells present in their CM samples, and 70%, 60% and 50%, respectively, had CD3+, CD117+ and CD20+ cells present.
Among the 10 patients, 6 added a DMARD to their treatment, 2 switched to another anti-TNF drug, and 2 switched to ustekinumab. All of the patients who added a DMARD showed a reduced disease activity score (DAS) at 6 months of follow-up, and among those who changed treatments, only patients who switched to ustekinumab had a reduced DAS at followup.
Despite the small study size, the authors say that the addition of a DMARD or a switch to ustekinumab showed greater efficacy than changing anti-TNF treatments in patients with IBD and paradoxical arthritis under anti-TNF treatment.
Reference
Alivernini A, Pugliese D, Tolusso B, et al. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open. 2018;4(1):e000667. doi: 10.1136/rmdopen-2018-000667.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarized the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.